Is DTC.CN overvalued or undervalued?

DTC.CN currently has a P/E ratio of -3.58. Relative to the sector average of 21.40, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Defence Therapeutics Inc. stock?

Defence Therapeutics Inc. trades on CNQ. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of DTC.CN?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying DTC.CN protect my money against local inflation?

Many investors in Latin America buy international stocks like DTC.CN to protect their purchasing power. Because DTC.CN is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy DTC.CN shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is DTC.CN a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well DTC.CN diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocksDTC.CN

Defence Therapeutics Inc.

CA$0.40+CA$0.02+5.26%

CNQ / CAD

Market cap

CA$30M

P/E

-3.6

EPS (TTM)

CA$-0.08

Dividend yield

0.00%

Beta

1.51

1Y return

-53.49%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$02021

$02022

$02023

$02024

$02025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.29Low
Current ratio3.37
Cash ratio3.03
Net margin0.0%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

DTC.CN-3.6
Healthcare sector median21.4
S&P 50022.0

Trades about 117% below its sector, cheaper than its peers on earnings.

Ratios

PEG0.09
Price to book4.36
EPS (TTM)CA$-0.08
Payout ratio0%
FCF yield-9.75%

Range & risk

CA$0.36CA$0.93

Trading in the lower third of its 52-week band

Beta1.51

Profile

What Defence Therapeutics Inc. actually does

Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.

CEO

Amie Phinney

Employees

Headquarters

Montreal, QC

Founded

2021-05-10

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save DTC.CN and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

DTC.CN has a beta of 1.51, which indicates how sensitive it has historically been to movements in its broader market. A beta above 1 suggests higher relative volatility than the market. Beta is based on historical data and does not predict future performance.

Defence Therapeutics Inc.